Penny Stock Spotlight: Sunpeaks Ventures Inc. (SNPK)
  • Stock Alert for Sunpeaks Ventures Inc. (SNPK)
  • Stock Alert for Sunpeaks Ventures Inc. (SNPK)
  • " />

    Stock Alert for Sunpeaks Ventures Inc. (SNPK)

    Sunpeaks Ventures Inc. (SNPK), through its wholly owned subsidiary, Healthcare Distribution Specialists LLC (HDS), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (OTC) branded multivitamins to the healthcare provider market.  HDS also owns and markets Clotamin®, a specialized OTC multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

    Share Statistics (09-Mar-12)  
    Symbol SNPK
    Current price $0.60  
    52wk Range: $0.28-$0.62  
    Avg Vol (3m): 98,710,138  
    Market Cap. 180.82M  
    Shares Outstanding n/a  

    Source:, SEC Filings.

    Investment Highlights

    Shares in Sunpeaks Ventures Inc. (SNPK) spiked as much as 44.2% to a fresh new high of $0.62 in Friday’s trade, two days after the Company canceled 50 million common shares of its authorized stock, with the intent of improving its overall capital structure and to increase shareholder value. The stock added $0.17 to close the session at $0.60, with over 98 million shares exchanged

    SNPK also attracted investor attention on Thursday after Company announced that it has reached final stages of negotiations to engage a well-known sports celebrity to act as national spokesperson for its Clotamin product.

    In late February, SNPK completed its acquisition of Healthcare Distribution Specialists LLC (HDS), a value-added distributor of hard-to-find and specialty drugs. HDS is the owner and marketer of Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin, a popular blood thinner that has a long list of known adverse drug and food interactions.

    Commenting on the Company’s deal with an NBA celebrity, Mackie Barch, CEO of SNPK, said: “We couldn’t be happier about identifying a current Clotamin user who also happens to be a legendary player and coach in the NBA. We believe that a strong marketing campaign featuring this individual could really help to boost Clotamin awareness and sales across the board.”

    SNPK plans to launch a national ad campaign featuring the famous player/coach designed to drive Clotamin into new markets and distribution channels upon successful conclusion of negotiations.

    SNPK last week provided an update regarding the development and market potential of Clotamin, which it claims to be the world’s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners)

    According to the Company’s release, which cited BioMed Trends in a report released by Global Industry Analysts Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015.  This can be attributed to an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

    Barch said that if the Company is able to penetrate just 5% of the market for Warfarin, which is one of the top 20 most prescribed drugs in the U.S. —  with over 32 million prescriptions being written each year for about 6 to 7 million patients, sales for Clotamin could potentially surpass $25 million annually. SNPK looks forward to ramping up its marketing and distribution efforts over the next few weeks and increasing awareness of Clotamin nationwide, Barch said.


    Financial Summary

    No financial data is available for SNPK.

    Technical Analysis


    Comparative Analysis

    No direct competitor comparison.

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *